Most Read Articles
Roshini Claire Anthony, 2 days ago

A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.

Rachel Soon, 4 days ago

Gels utilizing Stichopus horrens (golden sea cucumber/gamat) extract show a similar efficacy to standard-of-care hydrogels for promoting wound healing, according to a prospective study.

2 days ago
Higher cancer symptom burden in elderly adults is associated with functional impairment, reports a recent study.
Jairia Dela Cruz, 6 days ago
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.

Dilution, formulation conditions do not impact in-use stability of rituximab biosimilars

12 Feb 2019

The in-use stability of rituximab biosimilar Rixathon/Riximyo is not affected by dilution and formulation conditions needed for intravenous infusion even under worst case condition in terms of product shelf life, temperature excursion, light exposure, dilution factor and infusion bag storage time over a period of 31 days, according to biological and physicochemical analyses of a recent study.

The investigators assessed the in-use biological and physicochemical stability of the Sandoz rituximab biosimilar, marketed under the trade names Rixathon and Riximyo in the European Union, upon preparation for intravenous infusion. They exposed three batches of Rixathon/Riximyo in the final month of the samples’ 36-month shelf life to room temperature and light for 14 days to recapitulate a major temperature excursion.

The biosimilars were diluted to the lowest allowable concentration of 1 mg/mL in 0.9% sodium chloride (NaCl) solution in either polypropylene or polyethylene infusion bags and stored for 14 or 30 days at 5±3°C. This was followed by an additional 24 hours at room temperature to simulate product handling.

Size exclusion and ion exchange chromatography, nonreducing SDS capillary electrophoresis, peptide mapping and complement-dependent cytotoxicity assay were used to analyse samples stored in infusion bags and to examine biological and physicochemical stability.

Analysis revealed no change over a 31-day period in molecular weight and charge variants, as well as deamidation, oxidation, overall composition or potency for Rixathon/Riximyo diluted to the lowest allowable concentration in 0.9% NaCl in either polypropylene or polyethylene infusion bags.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 2 days ago

A subgroup of patients with HBeAg-negative chronic hepatitis B virus (HBV) infection who ceased their long-term nucleotide analogue treatment maintained virological suppression, pointing to a group of patients who may be suitable for treatment cessation, according to a recent study.

Rachel Soon, 4 days ago

Gels utilizing Stichopus horrens (golden sea cucumber/gamat) extract show a similar efficacy to standard-of-care hydrogels for promoting wound healing, according to a prospective study.

2 days ago
Higher cancer symptom burden in elderly adults is associated with functional impairment, reports a recent study.
Jairia Dela Cruz, 6 days ago
Use of mirabegron in the treatment of men with overactive bladder (OAB) appears to effectively alleviate urgency and storage symptoms, but not reduce the frequency of micturition episodes, according to data from the MIRACLE study.